Nightingale Health Plc has rolled out a remote blood collection kit for its medical research and clinical trial customers. This launch follows the company's acquisition of the worldwide license and rights to the Velvet(TM) self-collection device in January 2023. Nightingale Kit and its self-collection device allow study participants to draw their own blood sample from a finger-prick.

This creates substantial flexibility and enables study designs that have previously been constrained by geographical and logistic limitations. Additionally, since Nightingale Health provides both sample collection and sample analysis, remote blood collection can be incorporated into studies in a seamless, cost-efficient way. The biomarkers analyzed for research use from the dry blood sample taken with Nightingale Kit cover a wide range of biological functions, including lipids (e.g., LDL cholesterol, HDL cholesterol, triglycerides, ApoA1, and ApoA), insulin sensitivity (amino acids), dietary intake (e.g., omega-3 and omega-6 fatty acids), chronic inflammation (GlycA), fluid balance (e.g., albumin), and kidney function (e.g., creatinine).